-
公开(公告)号:US11376328B2
公开(公告)日:2022-07-05
申请号:US16609029
申请日:2018-04-27
申请人: Astellas Pharma Inc.
发明人: Takatsune Yoshida , Hiroyuki Kojima , Yoshiaki Umemoto , Sachie Namiki , Akira Takagi , Ken Shimada
IPC分类号: A61K47/32 , A61K31/4245 , A61K31/439 , A61K31/4422
摘要: Provided is a pharmaceutical composition in which the solubility and/or dissolution properties of a poorly-soluble drug can be improved. The pharmaceutical composition comprises a poorly-soluble drug, and polyvinyl alcohol having a saponification degree of 63 mol % or more and 67 mol % or less.
-
公开(公告)号:US09408835B2
公开(公告)日:2016-08-09
申请号:US14779328
申请日:2014-03-28
申请人: ASTELLAS PHARMA INC.
发明人: Seiji Takae , Hiroyuki Kojima , Atsushi Sakurai , Tetsuya Tamura , Hiroaki Tasaki , Atsushi Muro
IPC分类号: A61K31/437 , A61K9/20 , A61K9/28
CPC分类号: A61K31/437 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2095 , A61K9/2806
摘要: A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.
摘要翻译: 含有作为活性成分的4 - {[(1R,2s,3S,5s,7s)-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b]吡啶-5 甲酰胺,其在酸性pH区域中的溶解度与中性pH区域的溶解度不同,具有快速的崩解性能和快速的药物溶解性以及期望良好的药物剂量依从性。 本发明的口服药物组合物含有4 - {[(1R,2s,3S,5s,7s)-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b] 5-甲酰胺或其药学上可接受的盐和亲水润滑剂,并且可用作口服给药的药物组合物,其具有快速的崩解性能和快速的药物溶解性以及期望良好的药物剂量依从性。
-
公开(公告)号:US09775832B2
公开(公告)日:2017-10-03
申请号:US15319355
申请日:2015-06-24
申请人: ASTELLAS PHARMA INC.
IPC分类号: A61K31/4184 , A61K47/38 , A61K9/00 , A61K9/20 , A61K9/28
CPC分类号: A61K31/4184 , A61K9/0053 , A61K9/145 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/28 , A61K9/2866 , A61K47/38
摘要: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.
-
-